<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912141</url>
  </required_header>
  <id_info>
    <org_study_id>C1 5201</org_study_id>
    <nct_id>NCT04912141</nct_id>
  </id_info>
  <brief_title>Prevention of Acute Kidney Injury in Patients With NSTEMI</brief_title>
  <acronym>AKI</acronym>
  <official_title>Conestat Alfa (a Recombinant Human C1 Esterase Inhibitor) for the Prevention of Acute Kidney Injury After Non-ST Elevation Myocardial Infarction: a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2, Dose-finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharming Technologies B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharming Technologies B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, multi-center, phase 2 clinical study in&#xD;
      patients with NSTEMI undergoing urgent coronary angiography. Approximately 220 patients with&#xD;
      CKD and acute NSTEMI, who are scheduled for an urgent coronary angiography (within 72 hours&#xD;
      after admission and/or diagnosis of NSTEMI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 220 patients with chronic kidney disease (CKD) and acute NSTEMI, who are&#xD;
      scheduled for an urgent coronary angiography (within 72 hours after admission and/or&#xD;
      diagnosis of NSTEMI) will be screened for the study. Only patients with acute NSTEMI presumed&#xD;
      to be a spontaneous myocardial infarction, related to atherosclerotic plaque rupture,&#xD;
      ulceration, fissuring, erosion, or dissection (i.e. type 1) are eligible. Written informed&#xD;
      consent will be obtained before urgent coronary angiography. Patients with NSTEMI will&#xD;
      typically undergo coronary angiography within 72 hours after admission and/or diagnosis of&#xD;
      NSTEMI. It is estimated that 70% of these patients will have PCI. Randomization will continue&#xD;
      until the 160th patient has had a PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, multicenter, phase 2, dose-finding.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary NGAL</measure>
    <time_frame>24 hours after PCI</time_frame>
    <description>Evaluation of the peak change of urinary NGAL, an established biomarker of AKI, within 24 hours after PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary NGAL</measure>
    <time_frame>within 24 hours after angiography</time_frame>
    <description>The peak change of urinary NGAL within 24 hours after angiography for the total group including PCI and non-PCI patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>within 72 hours after angiography</time_frame>
    <description>The incidence of acute kidney injury (AKI) as defined by a serum creatinine change of ≥26.5 µmol/L or a serum creatinine change of ≥1.5 times baseline within 72 hours after angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cystatin C</measure>
    <time_frame>24 hours after angiography</time_frame>
    <description>The incidence of a serum cystatin C change of ≥10% 24 hours after angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin T</measure>
    <time_frame>within 72 hours after angiography</time_frame>
    <description>The change of troponin T within 72 hours (area under the curve, AUC0-72) after angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin T</measure>
    <time_frame>measured once at 72 hours after angiography</time_frame>
    <description>The peak change of troponin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatine kinase</measure>
    <time_frame>measured once at 72 hours after angiography</time_frame>
    <description>The peak change of creatine kinase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal pro-brain natriuretic peptide</measure>
    <time_frame>at 72 hours after angiography</time_frame>
    <description>N-terminal pro-brain natriuretic peptide (NT-proBNP) measured once at 72 hours after angiography</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Non-ST Elevation Myocardial Infarction (NSTEMI)</condition>
  <arm_group>
    <arm_group_label>Conestat alfa 50 U/kg - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 U/kg conestat alfa pre-angiography and placebo 3 hours after the first dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conestat alfa 50 U/kg - Conestat alfa 50 U/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 U/kg conestat alfa pre-angiography and 3 hours after the first dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conestat alfa 100 U/kg - Conestat alfa 50 U/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 U/kg conestat alfa pre-angiography and 50 U/kg conestat alfa 3 hours after the first dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pre-angiography and 3 hours after the first dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conestat alfa or placebo</intervention_name>
    <description>Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).&#xD;
Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line.</description>
    <arm_group_label>Conestat alfa 100 U/kg - Conestat alfa 50 U/kg</arm_group_label>
    <arm_group_label>Conestat alfa 50 U/kg - Conestat alfa 50 U/kg</arm_group_label>
    <arm_group_label>Conestat alfa 50 U/kg - Placebo</arm_group_label>
    <arm_group_label>Placebo - Placebo</arm_group_label>
    <other_name>Ruconest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed Consent as documented by a signature and date of the patient&#xD;
&#xD;
          2. Age 18-85 years&#xD;
&#xD;
          3. Acute NSTEMI as anticipated to be type 1 (expert opinion by the cardiologist before&#xD;
             coronary angiography) and scheduled for urgent coronary angiography&#xD;
&#xD;
          4. Documented kidney disease existing for ≥3 months OR Two estimated glomerular&#xD;
             filtration rate (eGFR) measurements of &lt;60ml/min/1.73m2 as calculated by the CKD-EPI&#xD;
             (Chronic Kidney Disease Epidemiology Collaboration) study equation and at least 6&#xD;
             hours apart OR eGFR of &lt;50 mL/min//1.73m2 as calculated by using the CKD-EPI study&#xD;
             equation at presentation&#xD;
&#xD;
          5. At least one of the following risk factors for AKI: diabetes mellitus, age &gt;60 years,&#xD;
             established cardiovascular disease, heart failure with reduced ejection fraction,&#xD;
             anemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to the class of drugs under study (C1 esterase inhibitors), e.g.&#xD;
             known hypersensitivity or allergy to class of drugs or the IMP&#xD;
&#xD;
          2. History or suspicion of allergy to rabbits&#xD;
&#xD;
          3. Women who are pregnant or breast feeding&#xD;
&#xD;
          4. ST elevation myocardial infarction or unstable angina&#xD;
&#xD;
          5. Cardiogenic shock requiring mechanical support&#xD;
&#xD;
          6. Non-cardiac comorbidity with expected survival &lt;6 months&#xD;
&#xD;
          7. Acute urinary tract infection (e.g. cystitis, pyelonephritis).&#xD;
&#xD;
          8. Liver cirrhosis (any Child-Pugh score)&#xD;
&#xD;
          9. Dialysis or eGFR &lt;20 and &gt;59mL/min/1.73 m2 at baseline (d0)&#xD;
&#xD;
         10. Incapacity or inability to provide informed consent&#xD;
&#xD;
         11. Participation in another study with investigational drug within 30 days preceding, and&#xD;
             during the present study&#xD;
&#xD;
         12. Previous enrolment into the current study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anurag Relan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharming Technologies BV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jurgen Schaale, MD</last_name>
    <phone>+31715247400</phone>
    <email>j.schaale@pharming.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Osthoff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenz Raber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Fernando Iglesias, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Istituto Cardiocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Moccetti, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

